Introduction
Lung cancer, the leading cause of cancer related mortalities in the United States (US Cancer Statistics Working Group, 2004) , is divided into two major subgroups, small cell lung carcinomas (SCLC) and nonsmall cell lung carcinomas (NSCLC). Depending on the type and stage of the disease, treatment for lung cancer includes tumor resection, chemotherapy, and radiation therapy. Recently, new approaches in the treatment of NSCLC have arisen from the discovery that the epithelial growth factor receptor (EGFR) is frequently overexpressed and activated in NSCLC (Dowell and Minna, 2005) . In lung cancer, loss of sequences within chromosome 3p is frequently seen in both SCLC and NSCLC, providing evidence of tumor suppressor genes (TSGs) in this chromosomal region (Girard et al., 2000; Zabarovsky et al., 2002) . The FUS1 gene has been identified in the 3p21.3 critical chromosomal region and is considered a novel TSG (Zabarovsky et al., 2002; Ji et al., 2002) . The mechanism of Fus1 tumor suppressor activity is unknown. A deletion mutant of FUS1 has been characterized (FUS1 (1-80)); it lacks the last 30 amino acids encoded by the FUS1 gene (Kondo et al., 2001; Ji et al., 2002) . Myristoylation of Fus1 at the Nterminus is required for the tumor suppressing function of FUS1 as myristoylation of Fus1 has been shown to increase in the half-life of the Fus1 protein (Uno et al., 2004) . The lack of Fus1 myristoylation has been found in NSCLC primary tumors (Uno et al., 2004) . Of interest, the myristic fatty acid, which is bound to the N-terminal segment of c-Abl isoform 1b, is thought to be involved in autoinhibition of c-Abl (Hantschel et al., 2003) .
The c-Abl protein is a tightly regulated non-receptor tyrosine kinase that is involved in the regulation of cell proliferation, cell survival, cell adhesion, cell migration and apoptosis. The c-Abl protein is located in both the nucleus and the cytoplasm. In the nucleus, c-Abl protein is known to be activated in response to DNA damage and contributes to apoptosis (Wang, 2000) . Cytoplasmic c-Abl is associated with growth factor receptor signaling that can affect cell mobility and cell adhesion (Taagepera et al., 1998) . Several studies have shown that c-Abl contains intramolecular interactions that provide autoinhibitory mechanisms (Pendergast, 2002; Pluk et al., 2002; Hantschel et al., 2003) . Studies have also found that c-Abl kinase activity is regulated by intermolecular interactions with negative regulators, which include Bcr (Liu et al., 1996; Ling et al., 2003) , PAG (Wen and Van Etten, 1997) and F-actin (Woodring et al., 2003) .
The c-Abl protein is widely expressed in all tissues and, until recently, oncogenically activated forms of Abl were believed to be restricted to hematopoietic malignancies (for example, Philadelphia chromosome þ chronic myeloid leukemia involving BCR-ABL fusions). A recent report has shown that c-Abl tyrosine kinase is activated in aggressive human breast cancer cell lines (Srinivasan and Plattner, 2006) . Activation of c-Abl was linked to EGFR expression and activation in the breast cancer cell lines (Srinivasan and Plattner, 2006) .
We have widened the scope of Abl kinase's role in solid tumors with the discovery there is an activated c-Abl kinase in human NSCLC cell lines, A549 and H1299 (Lin J, Sun T, Ji L, Minna J, Roth J and Arlinghaus R. Activated c-Abl in FUS1 haploinsufficient NSCLC. 96th Annual American Association for Cancer Research, April 2005). Of note, both the A549 and H1299 NSCLC cell lines are known have the 3p21.3 deletion and are deficient in the Fus1 protein (Kondo et al., 2001; Ito et al., 2004) .
Results
A stearate-Fus1 peptide inhibits the tyrosine kinase activity of c-Abl Fus1 is a TSG associated with NSCLC (Kondo et al., 2001; Zabarovsky et al., 2002) . A C-terminal deletion mutant of FUS1 was isolated from a lung cancer tumor cell line, which encodes the first 80 amino acids of the 110-amino-acid wild-type Fus1 protein (Kondo et al., 2001) . We synthesized a stearate-Fus1 peptide (KLRRVHKNLIPQGIVKLDHR) originating from sequences that are deleted in the C-terminal truncated mutant FUS1. This peptide strongly inhibited a bacterially purified Abl in a cell-free kinase assay using Crk, a known Abl substrate (Feller et al., 1994) , as a target (Figure 1a) . Surprisingly, the Fus1 peptide lacking the stearate N-terminal moiety was inactive as an Abl kinase inhibitor (Figure 1b) . Stearate alone was also not inhibitory. A stearate-modified Bcr peptide, GQSSRVEPSPTTYRMFDIC, which has about the same number of amino acids as the stearate Fus1 peptide, did not have any inhibitory effect on the bacterially purified 45 kDa recombinant Abl kinase ( Figure 1c) . Next, we assayed the effects of the stearate Fus1 peptide against a full-length purified human c-Abl. An insect purified human full-length active c-Abl was used in a cellfree kinase assay using a known peptide target of c-Abl, EAIYAAPFAKKK. Only the stearate Fus1 peptide was able to decrease the phosphorylation of the target peptide when compared to the stearate Bcr peptide and nonstearate Fus1 peptide (Figure 1d ). Together, these results indicate that both the stearate moiety and the amino-acid sequences within the Fus1 peptide were necessary for the inhibition of the c-Abl kinase.
The c-Abl tyrosine kinase is activated in NSCLC cell lines We examined several NSCLC cell lines for the presence of activated c-Abl (Figure 2 ). The NSCLC cell lines A549 and H1299 contained a tyrosine kinase-active c-Abl protein as determined immune complex kinase assays (Figure 2a ). In contrast, normal lung fibroblast cell line CCD16 did not express an activated c-Abl tyrosine kinase. Lysates of the NSCLC cell lines also contained a tyrosine-phosphorylated c-Abl protein, as shown by immune complex western blot (Figure 2b ). 
Imatinib inhibits colony formation of NSCLC cells
Imatinib mesylate (Gleevec) is widely known for its ability to inhibit the tyrosine kinase activity of c-Abl and Bcr-Abl (Buchdunger et al., 1996) . A previous study has shown that imatinib inhibited the growth of NSCLC cell line A549 in vitro (Zhang et al., 2003) . We therefore tested the effects of imatinib on colony formation of H1299 cells in soft agar (Figure 4 ). Imatinib treatment (concentrations 1-5 mM) strongly inhibited the colonyforming ability of H1299 cells; both the number and size of colonies were inhibited (Figure 4 ). We note that imatinib had little effect on the proliferation of the H1299 cells in cell culture. So the effects of imatinib were confined to the oncogenic behavior of H1299 cells, as measured by formation of growth of the cells in soft agar. (Liu et al., 1993) . The immune complex was pulled down using protein A beads and subjected to either kinase assays or western blotting. 32D cells expressing Bcr-Abl were used as a positive control. Normal human lung fibroblast, CCD16 and 32D cells expressing Bcr-Abl were used as negative and positive controls, respectively. (b) Anti-phosphotyrosine western blotting demonstrates that NSCLC cell lines A549 and H1299 have an active c-Abl tyrosine kinase while normal human lung fibroblast CCD16 lack an active c-Abl tyrosine kinase. Phosphotyrosine c-Abl was detected by anti-phosphotyrosine antibody 4G10 and c-Abl was detected by monoclonal anti-Abl antibody 8e9. Transformed Rat 1cells (Rat1 SH2) that express activated c-Abl was used a positive control (Ling et al., 2003) . ( 
Discussion
Previous studies have demonstrated that FUS1 has antitumor activity (Kondo et al., 2001; Ji et al., 2002) , but targets of the FUS1 gene have not been identified. In our studies, c-Abl was found to be negatively regulated by Fus1. Using a stearate Fus1 peptide derived from sequences lacking in the mutant FUS1 (1-80) (Kondo et al., 2001) seen in some NSCLC patients, we were able to inhibit the recombinant Abl kinase's ability to phosphorylate Crk, a normal target of c-Abl (Feller et al., 1994) (Figure 1 ). Of note, increased expression of c-Crk is associated with aggressive phenotype in lung adenocarcinoma (Miller et al., 2003) . Our results also show that only the stearic acid-modified form of the At 48 h post-transfection, COS1 cells were harvested and lysate was incubated with a polyclonal N-terminal Fus1 antibody. The immune complex was pulled down using protein A beads and subjected to western blotting. Phosphotyrosine c-Abl was detected by anti-phosphotyrosine antibody 4G10 and the same blot was stripped and re-probed with monoclonal anti-Abl antibody 8e9.
Oncogenic activation of c-Abl in NSCLC J Lin et al
Fus1 peptide had inhibitory effects on purified c-Abl kinase (Figure 1) . It has been shown that the myristoylation of FUS1 is required to produce the tumor suppression effects of FUS1 (Uno et al., 2004) . Coincidentally, the N terminus of c-Abl (isoform 1b) also contains a myristate residue, which has been implicated in the autoinhibition of c-Abl (Hantschel et al., 2003) . Functional interaction of wild-type Fus1 and c-Abl was shown in cells by co-expression assays in COS1 cells (Figure 3) . Phosphorylation of tyrosine 412 is a critical step that leads to the activation of c-Abl kinase (Brasher and Van Etten, 2000) . Co-expression of wild-type FUS1 and c-ABL led to a significant decrease in both the total (Kondo et al., 2001) , or the EV (Figure 3 ). This C-terminal deletion form of Fus1 lacks the peptide sequences, which are shown to inhibit c-Abl in kinase assays (Figure 1 ). In addition, it appears that Fus1 and c-Abl are in complex, as Fus1 and c-Abl co-precipitate with each other in IP assays (Figure 3a and d) . Of note, the C-terminal truncated Fus1 still binds to c-Abl, but does not decrease phosphotyrosine-labeled c-Abl. The C-terminus of Fus1, the sequences found in the inhibitory Fus1 peptide, must contain a critical sequence that leads to the decrease of c-Abl kinase activation. These findings provide strong evidence for direct inhibition of c-Abl tyrosine kinase by the Fus1 protein.
Our studies have also demonstrated that NSCLC cell lines express the tyrosine kinase-active c-Abl (Figure 2 ). This result is interesting considering that c-Abl is a tightly regulated tyrosine kinase and its oncogenicity is usually associated with oligomeric sequences in a chimeric protein (for example, Bcr-Abl and Tel-Abl) in leukemia cells. It is also important to note that c-Abl is not overexpressed in these human NSCLC cell lines. In support of our findings showing activation of c-Abl in NSCLC lines, treatment of a NSCLC cell line with imatinib strongly inhibited colony formation in soft agar (Figure 4) . Therefore, our findings identify c-Abl as a possible target of the TSG product FUS1 and indicate that c-Abl maybe a significant contributor to the oncogenicity of some forms of NCSLC, particularly those patients who are defective in FUS1 expression.
In previous studies, reduced expression of FUS1 or expression of defective mutants of FUS1, such as C-terminal deletion mutant of Fus1 (Kondo et al., 2001 ) (which lacks the c-Abl inhibitory sequence (Figure 1) ) or expression of the myristoylated mutant (G2A) form of Fus1 (Uno et al., 2004) (the fatty acid stearic acid is required for the c-Abl inhibitory activity of the Fus1 inhibitory peptide (Figure 1) ), are suggestive of an important role of Fus1 in controlling c-Abl and the oncogenic behavior of NSCLC cells. In support of the role of Fus1 in the regulation of c-Abl, we showed that forced expression of a full-length and functional Fus1 protein in H1299 cells induced apoptosis and inhibited the tyrosine kinase activity of c-Abl (Figure 5b ). Of interest, not only was the c-Abl tyrosine kinase activity inhibited by forced Fus1 expression, but Fus1 expression in H1299 cells led to the reduction of the c-Abl protein in these cells (Figure 5b) . Treatment of c-Abl immune complexes with the inhibitory stearate Fus1 peptide also reduced the level of c-Abl in these immune complexes in a dose-dependent manner (Figure 5d) . Moreover, the non-stearate form of the Fus1 peptide and the stearate Bcr peptide had no effects on the level of c-Abl protein. On the basis of our previous studies with anti-Abl immunoprecipitates from Bcr-Abl þ cells (Samanta et al., 2006) , the degradative forces responsible for reduction of c-Abl protein in the immune complex are in the putative c-Abl network of proteins, or contaminating degradation enzymes in the immunoprecipitate are degrading the c-Abl in the c-Abl immune complex treated with stearate/Fus1 peptide. In summary, these findings suggest that Fus1 may negatively regulate the stability of c-Abl in lung cells.
Further, the facts that c-Abl tyrosine kinase can be activated downstream of EGFR via Src kinase (Plattner et al., 1999) and c-Abl plays a role in breast cancers overexpressing EGFR (Srinivasan and Plattner, 2006) strengthen the possibility of c-Abl contributing to the oncogenicity of NSCLC, especially since our studies show that the deficiency of expression of the functional FUS1 TSG contributes to increased active c-Abl kinase. Further, a recent study has shown that activated Abl kinase has a novel role in the regulation of EGFR endocytosis. The study shows that active Abl kinase phosphorylates EGFR and impairs EGFR internalization (Tanos and Pendergast, 2006) . Thus, it seems likely that the well-known c-Abl inhibitor, imatinib, may have potential for the successful treatment of some forms of NSCLC.
Materials and methods

Cell lines and reagents
The human NSCLC cell lines, A549 and H1299, were obtained from Dr John Minna and colleagues. A549, H1299 and 32D P210 cells were cultured in RPMI (Invitrogen, Carlsbad, CA, USA) with 10% fetal bovine serum (FBS) and penicillin/ streptomycin (Cambrex, Walkersville, MD, USA). Normal human lung fibroblast cell line, CCD16, was obtained from Dr Ray Meyn and were cultured in Alpha MEM (Invitrogen) with 10% FBS, 1 mM non-essential amino acid mixture (Cambrex), MEM essential vitamin mixture (100 Â ) (Cambrex), and penicillin/streptomycin. COS1 cells and Rat 1 SH2 cells were cultured in Dulbecco's modified Eagle's medium (DMEM) (Invitrogen) with 10% FBS and penicillin/streptomycin. Imatinib mesylate was purchased from the MD Anderson pharmacy and dissolved in sterilized Millipore water. PA was purchased from Invitrogen.
Kinase assays
Cell-free kinase assays using a bacterially purified, constitutively activated, commercial truncated 45 kDa Abl containing only the SH2 and kinase domain (New England Biolabs, Ipswich, MA, USA) were performed according to the manufacturer's instruction using g-32 P ATP mixed with 100 mM cold ATP. GST-Crk was prepared as described and used as a substrate for the Abl tyrosine kinase. Reactions were run on an 8% SDS-PAGE gel and exposed to phosphoimager. Cell-free kinase assays, using an insect-purified, human, fulllength active Abl (Upstate, Lake Placid, NY, USA), were performed as described by the manufacturer's instructions, using the suggested Abl target peptide, EAIYAAPFAKKK. Immune complex kinase assays used procedures as described previously (Liu et al., 1996) . The Abl target peptide absorbs to Whatman P81 filters and the filters in triplicate are counted in a liquid scintillation spectrometer.
Immunoprecipitation and western blotting These procedures were described previously (Liu et al., 1996) . Antibodies used were Abl antibody P6D, raised against c-Abl 51-64 residues (Liu et al., 1993) , anti-Abl SH2 domain antibody, 8e9, anti-phosphotyrosine antibody 4G10 (Upstate, Charlottesville, VA, USA), anti-Abl-phosphotyrosine 245 (Abcam, Cambridge, MA, USA), anti-Abl-phosphotyrosine 412 (Abcam), and Fus1 antibodies were obtained from Dr Lin Ji.
Co-transfection assays c-ABL was co-transfected with either wild-type full-length FUS1 (1-110), truncated FUS1 (1-80), or EV in COS1 cells. Fugene 6 (Roche, Indianapolis, IN, USA) was used for the co-transfection assay.
Generation of stable expressing FUS1 H1299 cell line Stable clones of human NSCLC H1299 cells were established by transfection with plasmid vectors containing wt-FUS1 or myristoylation-deficient mutant FUS1 (mt-FUS1) genes under the control of a PA-inducible promoter and with a Neomycinresistant gene as a selective marker. The cell clone containing EV without the gene insert was used as a negative control.
Colony formation in soft agar assays and foci formation H1299 cells were seeded on to dishes in 0.35% agar; cells were maintained until visible colonies were observed. Plates were stained with crystal violet.
TUNEL assay
Apoptosis was measured by flow cytometry using a terminal deoxynucleotidyl TUNEL-based fluorescence-activated cell sorter (FACS) analysis. Cells were fixed in 1% paraformaldehyde, permeabilized with 70% ethanol, washed with PBS and stained with propidium iodide (PI) solution containing 40 g/ml of PI and 10 g/ml DNase-free RNase A. DNA fragmentation was analysed by FACS.
